Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis.
Soliotis
F
F
Glover
M
M
Jawad
A S M
AS
D000328:Adult; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000473:pathology; D003875:Drug Eruptions / Q000209:etiology* / Q000473:pathology; D004890:Erythema / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D000077339:Leflunomide; D011743:Pyrimidines / Q000037:antagonists & inhibitors*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D007074:Immunoglobulin G; D007555:Isoxazoles; D011743:Pyrimidines; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000077339:Leflunomide; C030986:pyrimidine; D000068800:Etanercept